Skip to Content
Merck
CN
All Photos(1)

Documents

Y0000382

Famotidine for system suitability

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
Famotidine, N′-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine
Empirical Formula (Hill Notation):
C8H15N7O2S3
CAS Number:
76824-35-6
Molecular Weight:
337.45
MDL number:
MFCD00079297
UNSPSC Code:
41116107
PubChem Substance ID:
329830928
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

famotidine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

N\C(N)=N\c1nc(CSCCC(=N)NS(N)(=O)=O)cs1

InChI

1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)

InChI key

XUFQPHANEAPEMJ-UHFFFAOYSA-N

Gene Information

human ... HRH2(3274)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Famotidine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

H2 histamine receptor antagonist; anti-ulcer agent

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

PHR1055

Famotidine, Pharmaceutical Secondary Standard; Certified Reference Material

F0005000

Famotidine, European Pharmacopoeia (EP) Reference Standard

Y0000409

Famotidine impurity D, European Pharmacopoeia (EP) Reference Standard

1269200

Famotidine, United States Pharmacopeia (USP) Reference Standard

1269243

Famotidine Related Compound D, United States Pharmacopeia (USP) Reference Standard

1269265

Famotidine Related Compound F, United States Pharmacopeia (USP) Reference Standard

1269221

Famotidine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1269232

Famotidine Related Compound C, United States Pharmacopeia (USP) Reference Standard

1269254

Famotidine Related Compound E, United States Pharmacopeia (USP) Reference Standard

BP653

Famotidine, British Pharmacopoeia (BP) Reference Standard

PHR2908

Famotidine Related Compound F, certified reference material, pharmaceutical secondary standard

PHR2909

Famotidine Related Compound B, certified reference material, pharmaceutical secondary standard

PHR2910

Famotidine Related Compound C

PHR2911

Famotidine Related Compound D

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Occupational allergic contact dermatitis from intermediate products in famotidine synthesis.
D Guimaraens et al.
Contact dermatitis, 31(4), 259-260 (1994-10-01)
[Famotidine--a new histamine H2 receptor blockader].
P Ia Grigor'ev et al.
Klinicheskaia meditsina, 69(4), 23-28 (1991-04-01)
M C Martinez
The Annals of pharmacotherapy, 33(6), 742-747 (1999-07-20)
To evaluate the use and potential benefit of famotidine in the management of schizophrenia. Clinical literature accessed through MEDLINE (February 1998-October 1998). Key search terms included famotidine, schizophrenia, and histamine. Schizophrenia is a complicated disorder associated with high morbidity if
H Echizen et al.
Clinical pharmacokinetics, 21(3), 178-194 (1991-09-01)
Famotidine is a potent histamine H2-receptor antagonist widely used in the treatment and prevention of peptic ulcer disease. After intravenous administration the plasma famotidine concentration-time profile exhibits a biexponential decay, with a distribution half-life of about 0.18 to 0.5h and
L P James et al.
Clinical pharmacokinetics, 31(2), 103-110 (1996-08-01)
Famotidine, an H2 receptor antagonist, has several potential advantages over cimetidine and ranitidine. These advantages include its potency, relatively longer elimination half-life, and lack of interaction with the cytochrome P450 isoforms. Eight studies addressing the use of famotidine in paediatric
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service